Prenatal Testing Options for Trisomy 21, 18 and 13 are Evolving – What You Should Know ...

Sequenom Laboratories was the first to market a noninvasive prenatal LDT for trisomies for chromosomes 21, 18 and 13.

With the Enhanced Sequencing Series, the test will begin reporting on select, clinically relevant microdeletions, including 22q11.2 deletion syndrome (DiGeorge), Cri-du-chat syndrome, Prader-Willi/Angelman syndrome, 1p36 deletion syndrome, as well as two additional trisomies (Trisomy 16 and Trisomy 22).

The test is intended for use in pregnant women at increased risk for fetal chromosomal aneuploidies and can be used as early as 10 weeks' gestation. Estimates suggest there are about 750,000 pregnancies at high risk for fetal aneuploidy each year in the United States. The MaterniT21 PLUS test is available exclusively through the Sequenom Laboratories as a testing service provided to clinicians

MATERNIT21™ PLUS All about pregnancy

Thank you for visiting this website regarding carrying out a non-invasive test for chromosomal aberrations. We would like to inform you about the technical and practical aspects of the MaterniT21 PLUS test. This laboratory test is carried out in the U.S. laboratories of a company called SCMM – Sequenom http://www.sequenomcmm.com/home/.

IMALAB Ltd. - http://www.imalab.cz/ is a partner of Sequenom. Practical implementation of the test involves genetic consultations, ultrasound, blood sampling, preanalytical sample preparation, transport to the U.S.A. and delivering results. The partner for the implementation of the clinical test is some centers in the Czech Republic. Our goal is not only to offer the test, but also to provide comfortable and good quality accommodation at a reasonable price, for patients traveling to Zlin.

We believe that this website answers all your questions. However, if you need any further information regarding the MaterniT21 PLUS test or organizational issues related to the test; please do not hesitate to contact us via the information section.